AF 2975

Drug Profile

AF 2975

Latest Information Update: 18 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Angelini Group
  • Class Eye disorder therapies
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Eye disorders

Most Recent Events

  • 18 Oct 2006 Discontinued - Phase-I for Eye disorders in Italy (Ophthalmic)
  • 02 Jul 1999 A clinical study has been added to the pharmacodynamics section
  • 20 Feb 1997 Phase-I clinical trials for Eye disorders in Italy (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top